Objective: We describe a novel congenital motor neuron disease with early demise due to respiratory insufficiency with clinical overlap with spinal muscular atrophy with respiratory distress (SMARD) type 1 but lacking a mutation in the IGHMBP2 gene.
Spinal muscular atrophy with respiratory distress (SMARD) is a rare autosomal recessive disorder of neonatal weakness and early respiratory failure (Online Mendelian Inheritance in Man [OMIM] #604320). 1 SMARD was first described in 1974 as a variant of Werdnig-Hoffmann disease (spinal muscular atrophy type I) but is distinguished by the prominence of early respiratory failure and distal muscle weakness or joint contractures. 2 Since discovery of the IGHMBP2 gene as a cause for SMARD, 3 appreciation of the clinical and genetic heterogeneity has been increasing. 2, 4, 5 IGHMBP2 is a ubiquitously expressed helicase that colocalizes with factors controlling RNA splicing in the cytosol and nucleus. 6 A role for IGHMBP2 in translation has been proposed based on colocalization in the cytoplasm with ribosomal proteins and ribosomal RNA (rRNA). 6, 7 As in many other disorders with motor neuron involvement, it is unclear why mutations in IGHMBP2 have a disproportionate effect on motor neurons. 8 Infants presenting with a SMARD phenotype but lacking mutations in IGHMBP2 are common, accounting for up to two-thirds of reported patients. 4, 9 We describe an infant who presented with distal weakness and primary respiratory failure associated with diaphragm paralysis but lacking a Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. mutation in the IGHMBP2 gene. We identified a de novo mutation in the LAS1-like (S cerevisiae) gene (LAS1L) by diagnostic exome sequencing. LAS1L is an X-linked gene that has a critical role in ribosomal biogenesis. 10 We provide evidence of pathogenicity using a zebrafish (Danio rerio) model and propose that disruption of ribosomal maturation may be a common pathogenic mechanism linking SMARD phenotypes caused by mutations in both IGHMBP2 and LAS1L. Exome sequencing and variant analysis. DNA from the proband and his parents was referred for diagnostic exome sequencing to Ambry Genetics (Aliso Viejo, CA). Genomic DNA was prepared for whole exome sequencing using the SureSelect Target Enrichment System (Agilent Technologies, Santa Clara, CA) according to the manufacturer's protocol. 11 Briefly, each DNA sample was sheared, blunt-end repaired, and tagged using indexed adapters. Coding exons and flanking intronic sequences were enriched using solution-based hybridization with oligonucleotide probes. The enriched exome libraries were then applied to the solid surface flow cell for clonal amplification and sequencing using paired-end, 100-cycle chemistry on the Illumina HiSeq 2000 (Illumina, San Diego, CA).
METHODS
Initial data processing and base calling, including extraction of cluster intensities, was done using RTA 1.12.4 (HiSeq Control Software 1.4.5). Sequence quality filtering was executed with the Illumina CASAVA software (version 1.8.2; Illumina, Hayward, CA). Sequence fragments were aligned to the reference human genome (GRCh37) and variant calls were generated using CASAVA. Exons plus at least 2 bases into the 59 and 39 ends of all the introns were analyzed. Analysis of variants focused on nonsense variants, small insertions and deletions, canonical splice variants, and nonsynonymous missense variants. Online databases, including the Human Gene Mutation Database, 12 dbSNP (Single Nucleotide Polymorphism Database), 13 1000 Genomes, 14 HapMap, 15 and online search engines (e.g., PubMed, OMIM), were used to search for known mutations and polymorphisms. Filtering included the sequential removal of common single nucleotide polymorphisms (SNPs), 39/59 UTR (untranslated region) variants, nonsplicerelated intronic variants, and synonymous variants. Annotated variants associated with known disorders in the Human Gene Mutation Database or OMIM database were protected in the filtering pipeline. Remaining variants were filtered based on family history and inheritance models. Variants were annotated with the Ambry Variant Analyzer to assess nucleotide and amino acid conservation (NIH Heart, Lung, and Blood Institute [NHLBI] Exome Sequencing Project and 1000 Genomes databases), [16] [17] [18] [19] [20] and predicted functional impact (Poly-Phen 21 and SIFT 22, 23 ). Assemblies and sequence alignments were viewed using IGV (Integrative Genomics Viewer software). 24 Candidate variants were confirmed using automated fluorescence dideoxy sequencing. Cosegregation analysis was performed using the trio and the 2 unaffected brothers (figure e-1A on the Neurology ® Web site at Neurology.org). Amplification primers were designed using PrimerZ. 25 PCR primers were tagged with established sequencing primers on the 59 end. Sequencing was performed on an ABI3730 (Life Technologies, Carlsbad, CA) using standard procedures.
LAS1L sequencing in the screening cohort. Validation of pathogenicity of las1l mutation in zebrafish. All zebrafish experiments were performed in strict accordance of guidelines from the University of Utah Institutional Animal Care and Use Committee, regulated under federal law (the Animal Welfare Act and Public Health Services Regulation Act) by the US Department of Agriculture and the Office of Laboratory Animal Welfare at the NIH, and accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Adult fish were bred according to standard methods. Embryos were raised at 28.5°C in E3 embryo medium and staged by time and morphology. 26 Morpholino and RNA injections. One-cell stage embryos were injected with translation-blocking or splice-blocking morpholinos (GeneTools, LLC, Philomath, OR) as previously described. 27 Morpholinos were targeted against zebrafish las1l, LOC561321 (NM_001126400.1). Sequence of the translationblocking morpholino was 59-CCCCACCGTTTCTTTCTTCAT-CTTC-39; sequence of the splice-blocking morpholino against exon 10 was 59-CTGCCACACAATGACAGAGAGGGCT-39. For rescue experiments, wild-type embryos were injected at the one-cell stage with 2 ng splice-blocking morpholino, 2 ng splice-blocking morpholino and 5 pg wild-type human LAS1L RNA (NM_031206.4), 2 ng splice-blocking morpholino and 5 pg mutant human LAS1L RNA (c.1430G.A), or 5 pg wild-type human LAS1L RNA. More than 50 embryos were scored for each condition at 24 hours postfertilization (hpf).
In situ hybridization and immunohistochemistry. Wholemount immunohistochemistry was performed as described. 28 Embryos at 24 hpf were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) overnight at 4°C, washed briefly in PBS, dehydrated stepwise from PBS to 100% MeOH, and stored in 100% MeOH at 220°C. Antibodies and dilutions included goat anti-mouse Alexa 488 1:500 (Invitrogen, Carlsbad, CA); mouse anti-SV2 1:300 (Developmental Studies Hybridoma Bank [DSHB]); mouse f59 1:5 (DSHB); mouse f310 1:20 (DSHB); and Cy-3 anti-rabbit 1:400. Apoptotic cells were stained using TUNEL (Millipore, Billerica, MA) as described. 19 Image acquisition and analysis were performed as described previously. 29 Embryos were processed and placed in a solution of 80% glycerol/20% PBST, and mounted on a glass slide with a #0 coverslip. NIH ImageJ software was used to merge slices to create maximal intensity z-stack projections.
las1l reverse transcription PCR. Total RNA from 24 hpf embryos was extracted using Trizol (Invitrogen), purified (Qiagen RNeasy mini-columns), and reverse-transcribed (SuperScript III First-Strand Invitrogen kit). Primers for las1l were used to amplify the region spanning exon 10; forward primer in exon 9: 59-TACATCGCCTCCTGGATCTC-39; reverse primer in exon 13: 59-TCAGATCCACTGGCTCCTCT-39.
LAS1L site-directed mutagenesis. LAS1L human complementary DNA (cDNA) in pDNR-LIB was obtained from Open Biosystems (clone ID 4079376). The QuikChangeII site-directed mutagenesis kit (Agilent) was used to change the cDNA position 1430 in from G to A, using forward primer 59-CTCACCTTGCTGGGCCAACCCCCAACT-39 and reverse primer 59-AGTTGGGGGTTGGCCCAGCAAGGTGAG-39. The resultant clone was Sanger-sequenced in both directions to validate the sequence change.
Electronic-database information. Accession numbers and
URLs for data in this article are as follows: Parents elected to withdraw support after they were counseled regarding the poor prognosis for successful extubation. Overall, the clinical picture was characteristic of a SMARD-like motor neuronopathy. Brain MRI, EEG, and routine CSF studies were unremarkable, as were serum lactate, urine organic acids, and plasma amino acids and acylcarnitines, suggesting that mitochondrial or metabolic disorders were unlikely. Initial genetic Variants in 2 X-linked genes, LAS1L (NM_031206.4; c.1430G.A, p.S477N) and NAP1L3 (NM_004538.5; c.926A.G, p.K309R), were notable for potential clinical relevance and predicted pathogenicity. The mother was heterozygous for the variant in NAP1L3 while the proband and both unaffected brothers were hemizygous, eliminating this variant by failure to cosegregate. This variant has been reported in dbSNP135 (rs146057748) with allele frequency of 0.003. The variant in LAS1L was not seen in the unaffected parents or siblings. In support of pathogenicity, this allele was not observed in 6,501 alleles studied in the NHLBI Exome Sequencing Project database and has not been reported in public databases. Furthermore, this position is conserved among vertebrate species (figure e-1, B and C) . Bioinformatic analyses including SIFT 23 and PolyPhen-2 21 both predict that this substitution is pathogenic.
Sanger-sequencing confirmation in the proband and screening of similarly affected infants. We screened 11 patients with early-onset severe motor neuronopathy phenotypes and normal SMN1 testing. Sequencing of the 14 exons of LAS1L revealed no variants from the reference sequence. Further, 103 deidentified male infants with presumed motor neuron disease were screened for mutations in exon 11 of LAS1L. All patients were negative for the c.1430G.A, p.S477N or other variants in exon 11. Unfortunately, these samples were not made available for additional analysis outside exon 11.
Zebrafish knockdown of las1l. We used a zebrafish model to rapidly test the pathogenicity of the LAS1L p.S477N substitution identified in the proband. LOC561321 (las1l) on zebrafish chromosome 5 is orthologous to human LAS1L. A threonine residue at position 386 in exon 10 of the zebrafish protein (NP_001119872.1) is conserved with the serine residue at position 477 in the human LAS1L (NP_112483.1; figure e-1C). To demonstrate the importance of Las1l in development of nerve and muscle in the zebrafish, we used a morpholino targeting the lasl1 translation initiation site to block translation of the las1l transcript. To demonstrate the importance of the region of the gene orthologous to the p.S477N substitution, we used a splice-blocking morpholino to induce skipping of exon 10. Knockdown of Las1l by both translation-blocking or by splice-blocking leads to early lethality and increased apoptosis in the brain, spinal cord, and body musculature ( figure 1, A-C) . A 2-ng dose of the splice-blocking morpholino led to skipping of exon 10, which contains the critical T386 residue orthologous to the p.S477N mutation seen in the proband (figure 1, D and E). Morphologically, embryos treated with the splice-blocking morpholino showed disrupted architecture of muscle and peripheral nerve (figure 2, A-F). Both fast and slow twitch muscle fibers were affected (figure 2, D and F). Significantly elevated levels of apoptosis were noted in the morphant embryos (figure 2, G and H), consistent with previous reports that LAS1L is necessary for cellcycle progression. 30 To demonstrate sufficiency of human LAS1L RNA to rescue the phenotype induced by spliceblocking of exon 10 in the zebrafish and to demonstrate pathogenicity of the p.S477N substitution, we performed rescue experiments. First, we injected fulllength human LAS1L RNA into zebrafish embryos after first injecting the splice-blocking morpholino to eliminate the native protein. Because the human RNA and zebrafish sequences lack primary sequence conservation, the splice-blocking morpholino had no activity against the human RNA. Second, we injected full-length human RNA carrying the mutation seen in the proband (c.1430G.A) into zebrafish embryos injected with the splice-blocking morpholino. Injection of wild-type but not mutant LAS1L RNA partially rescued the dysmorphic effects of the splice-blocking morpholino ( figure 3 ). We conclude that the human p.S477N mutation seen in the proband leads to impaired function or loss of function of LAS1L. DISCUSSION We describe a congenital progressive motor neuron disease associated with a mutation in LAS1L, a key component of the ribosome biogenesis pathway. The phenotype overlaps considerably with SMARD type 1, caused by mutations in the IGHMPB2 gene, and includes distal limb contractures, axial hypotonia with preserved antigravity limb movements, and progressive respiratory failure. Neurophysiologic studies demonstrate a lengthdependent motor neuronopathy. Diagnostic exome sequencing identified a de novo mutation in LAS1L (c.1430G.A, p.S477N), an X-linked gene important in ribosomal biogenesis. The p.S477N substitution identified in the proband is outside known functional domains, but is highly conserved in vertebrate species. Pathogenicity of this allele is supported by its absence in control populations, high level of conservation, and SIFT and PolyPhen-2 analyses that predict pathogenicity. The early lethality and disruption of muscle and peripheral nerve architecture in zebrafish with morpholino knockdown strategies targeting las1l and rescue with human wild-type RNA but not mutant (c.1430G .A) RNA further support its pathogenicity.
To date, mutations in LAS1L have not been reported with any human phenotype; however, the ortholog in Saccharomyces cerevisiae, LAS1 is essential for cell viability and proliferation. 31 Depletion of Las1 results in failure of budding and cell-cycle arrest. Recent studies have demonstrated an important role for LAS1L in ribosomal biogenesis. 10, 30 Ribosomal biogenesis is a complex process coordinating production of 4 ribosomal RNAs from 2 different RNA templates, 80 core proteins, and numerous associated proteins (figure 4). 16 Loss of LAS1 in S cerevisiae interrupts the production of the large, 60S ribosomal subunit by disruption of the processing of the 47S pre-rRNA at the second intervening sequence (ITS2), which separates the 5.8S and 28S rRNA sequences. 30, 32 Processing of the 28S rRNA is dependent on the five friends of methylated Chtop (5FMC) complex, which includes LAS1L, SENP3, WDR18, TEX10, and PELP1. Collectively, this complex coordinates the rate of formation of the large ribosomal subunit and controls its distribution from the nucleolus. 33, 34 It is unclear how a deficiency in LAS1L results in specific damage to motor neurons. Similar to LAS1L, recent studies on the function of IGHMBP2 have suggested a role for IGHMBP2 in ribosomal biogenesis and translation. A close physical association of the IGHMBP2 protein with ribosomes in the cytoplasm suggests a link with the translation machinery. 35 Furthermore, a role in ribosomal biogenesis is suggested by a close physical interaction in the nucleolus between IGHMBP2, ABT1, and the U3 snoRNP, which direct the processing of the 59 external transcribed sequence of the 45S pre-rRNA. 7, 36 Of particular interest is the finding that the Abt1 gene in mice acts as a modifier of severity of the nmd mouse, a model for SMARD that harbors a mutation in Ighmbp2. 7 While direct interactions between LAS1L and IGHMBP2 have not been demonstrated, both have roles in ribosomal biogenesis via processing of the 45S pre-rRNA. The convergence of mechanisms associated with ribosome biogenesis from IGHMBP2 and LAS1L, both resulting in SMARD phenotypes, suggests the importance of this pathway in motor neuron development and/or in the maintenance of distal connectivity once initially established. Other genes important in ribosomal biogenesis may be candidates for mutation screening in patients with SMARD phenotypes that lack mutations in LAS1L or IGHMBP2. While mutations in LAS1L appear to be a rare cause of the SMARD phenotype, identification of additional patients with SMARD or other motor neuron disease phenotypes with mutations in LAS1L may provide insight into the vulnerability of motor neurons to defects in the ribosomal biogenesis pathway.
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